{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Reported by type, frequency, and severity.","groups":[{"description":"Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Trametinib)"},{"description":"Patients who develop progressive disease on trametinib monotherapy or achieve less then a PR after 4 cycles of treatment will have the option to continue on trametinib with the addition of GSK2141795","id":"OG001","title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From time of treatment start until treatment completion, an average of 1 year","title":"Incidence of Adverse Event Reactions Reported According to CTCAE v4.0","type":"SECONDARY","unitOfMeasure":"Adverse Events"}